Aripiprazole CAS 129722-12-9 Maʻemaʻe >99.0% (HPLC) API

ʻO Aripiprazole (CAS: 129722-12-9) kahi ʻano hou o ka lipid soluble quinoline derivatives, ʻo kona ʻano hopena pharmacological ʻaʻole ia wale ka postsynaptic dopamine D2 receptor antagonist, akā ʻo ka presynaptic dopamine D2 receptor agonist, hiki nō hoʻi. hoʻoulu i nā mea hoʻokipa D1, D3, D4.ʻO Aripiprazole ka lua o ka hanauna atypical antipsychotic a me ka anti-depressant me ka hana agonist hapa ma ka dopamine D2 a me ke serotonin 5-HT1A mau mea hoʻokipa a me ka hana antagonist ma nā mea hoʻokipa serotonin 5-HT2A.ʻO nā waiwai Ki he 0.34 nM, 0.8 nM, 1.7 nM, a me 3.4 nM, i kēlā me kēia, no ka dopamine D2 a me D3, serotonin 5-HT1A a me 5-HT2A nā mea loaʻa.Hoʻohana ʻia ʻo Aripiprazole no ka mālama ʻana i ka schizophrenia a me nā maʻi psychotic pili.Ua hoʻolaha ʻo Bristol-Myers Squibb a me Otsuka Pharmaceutical Company ua ʻae ka European Union iā Abilify (Aripiprazole) i ka mālama ʻana i ka palapala noi papa inoa schizophrenia.Hoʻopilikia ka schizophrenia i ka 1% o ka heluna kanaka o ka honua, a ʻoi aku ka nui o ka poʻe ʻōpio.Hoʻopilikia ka schizophrenia i ka noʻonoʻo, ka mana o ka naʻau a me ka hiki ke hoʻoholo i ka mea maʻi.Loaʻa i nā maʻi maʻi Schizophrenia-maikaʻi nā hōʻailona e like me ka hallucinations a me ka hoʻopunipuni, nā mea maʻi me nā hōʻailona maikaʻi ʻole ka haʻalele ʻana i ka nohona, ka nele o nā hoʻololi o ka naʻau.I ka makahiki 2002, ua ʻae ka FDA iā Abilify no ka mālama ʻana i ka maʻi schizophrenia, nona nā ikaika ʻelima: 5 mg, 10 mg, 15 mg, 20 mg a me 30 mg, mai kona ʻae ʻia.